A Phase II Study of CTLA Blockade by Ipilimumab plus Androgen Suppression Therapy in Patients with an Incomplete Response to AST Alone for Metastatic Prostate Cancer
The purpose of this study is to learn how effective the study drug (Ipilimumab, MDX-010, BMS-734016) is against prostate cancer which has stopped responding to treatment with hormone therapy. Also, this study will be looking at the effects of the study drug on the body, and how it effects your immune system.
* Subjects should have confirmed adenocarcinoma of the prostate that has spread outside of the prostate
* Subjects should not have HIV and/or hepatitis B and/or C.
* Subjects should not have brain metastases.
18 - 100
Healthy Volunteers Needed
Duration of Participation
Up to 5 years
Clinical Trials Information Line: Phone 503-494-1080 or email@example.com